🎯 3 free searches remaining
Rapid Dose Therapeutics Corp. specializes in drug delivery technologies aimed at improving patient outcomes in Canada. While the company boasts a strong gross margin of 55.9%, it faces significant concerns with a low current ratio of 0.13 and negative margins across EBITDA and net income, indicating financial instability. The recent 14.81% price increase may reflect market optimism, but the overall financial health score of 27/100 suggests caution, particularly given the high leverage and poor return on assets.
Loading financial metrics...
Company has $9K in cash but burned $240K last quarter. At this burn rate, only 0.0 quarters of runway remain without additional financing.
Company posted a loss of $-4.6M over the last year, representing 175.0% of revenue.
Debt of $5.7M is 661.7x the company's cash position of $9K.
Gross profit margin decreased from 61.0% to 51.9% compared to last year.
Exceptional revenue growth of 95.8% YoY demonstrates strong market demand and competitive positioning.
Operating margin expanded by 146.5pp, demonstrating strong operational leverage.
Strong gross margin of 51.9% reflects healthy unit economics.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.